Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 575

Sort by

Sort Order Select

Journal Articles

Deletion 17p: a matter of size and number?

Sonja Zweegman, Niels W. C. J. van de Donk

Blood (2021) 137 (9): 1135–1136.

https://doi.org/10.1182/blood.2020009102

Published: 2021

Journal Articles

Infectious mononucleosis affecting sinonasal mucosa

Elham Vali Betts, Regina Gandour-Edwards

Blood (2019) 134 (22): 1996.

https://doi.org/10.1182/blood.2019002978

Published: 2019

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL

Cosmin A Tegla, MD, Alberto M Herrera, MS, Angelina M Seffens, BS, Melania H Fanok, PhD, George Dean, MD, John Kawaoka, MD, Mary E Laird, MD, Yi Fulmer, PhD, Andreas Willerslev-Olsen, PhD, Kenneth B. Hymes, MD, Jo-Ann Latkowski, MD, Niels Odum, MD DMSci, Stefan Feske, MD, Bo Shopsin, MD PhD, Victor Torres, PhD, Marshall E. Kadin, MD, Larisa J Geskin, MD, Sergei B. Koralov, PhD

Blood (2019) 134 (Supplement_1): 659.

https://doi.org/10.1182/blood-2019-131917

Published: 2019

Journal Articles

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Gautam M. Borthakur, MD, Olatoyosi Odenike, MD, Ibrahim Aldoss, MD, David A. Rizzieri, MD, Thomas Prebet, MD PhD, Dimple A. Modi, PhD, Rujuta Joshi, Beibei Hu, Yan Sun, PhD, Johannes E. Wolff, MD, Brian A Jonas, MD PhD

Blood (2019) 134 (Supplement_1): 539.

https://doi.org/10.1182/blood-2019-126854

Published: 2019

Journal Articles

FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults

Jibran Durrani, Hassan Awada, MD, Wenyi Shen, MD, Cassandra M Kerr, MS, Vera Adema, PhD, Sunisa Kongkiatkamon, Ashwin Kishtagari, MBBS, Samuel Li, Yasunobu Nagata, MD PhD, Sanghee Hong, MD, Aziz Nazha, MD, Bhumika J. Patel, MD, Yogenthiran Saunthararajah, MD, Hetty E. Carraway, MD MBA, Valeria Visconte, PhD, Seth J. Corey, MD, Mikkael A. Sekeres, MD MS, Thomas Laframboise, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 452.

https://doi.org/10.1182/blood-2019-130142

Published: 2019

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Santiago Barrio, PhD, Larissa Haertle, PhD, Umair Munawar, MSc, Lucia Martin, Isabel Cuenca, MSc, Cornelia Vogt, MSc, Andoni Garitano-Trojaola, PhD, Matteo Claudio Da Via', MD, Miguel Gallardo, PhD, Thorsten Stuehmer, PhD, Hermann Einsele, MD, Leo Rasche, MD, Joaquin Martinez-Lopez, MD PhD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 1807.

https://doi.org/10.1182/blood-2019-130812

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, Frédéric Baron, MD PhD, Chantal Lechanteur, Etienne Baudoux, Alexandra Briquet, Dominik Selleslag, MD, Johan A. Maertens, MD PhD, Xavier Poire, Wilfried Schroyens, MD PhD, Carlos Graux, Rik Schots, Pierre Zachée, Aurelie Ory, Julie Herman, Tessa Kerre, Yves Beguin, MD PhD

Blood (2019) 134 (Supplement_1): 37.

https://doi.org/10.1182/blood-2019-129992

Published: 2019

Journal Articles

Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation

Chenglong Li, MDand PhD, Xi Yang, Jingying Dai, PhD, Ningning Tang, Hong Zheng, MD PhD, Chunsen Wang, MD, Xiaobing Huang

Blood (2019) 134 (Supplement_1): 1966.

https://doi.org/10.1182/blood-2019-126632

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 3035.

https://doi.org/10.1182/blood-2019-123419

Published: 2019

Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3036.

https://doi.org/10.1182/blood-2019-126508

Published: 2019

Journal Articles

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)

Liana E Gynn, BSc, Elizabeth Anderson, PhD, Gareth M Robinson, PhD, Sarah Anne Wexler, MBBS, MRCP, FRCPath, Gillian Upstill-Goddard, Christine Cox, Rhys Gareth Morgan, PhD, Jennifer E May, PhD BSc

Blood (2019) 134 (Supplement_1): 2492.

https://doi.org/10.1182/blood-2019-122891

Published: 2019

Journal Articles

UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing

Fengshan Liang, PhD, Adam S Miller, PhD, Carolilne Tang, Patrick Sung, PhD, Gary M. Kupfer, MD

Blood (2019) 134 (Supplement_1): 2497.

https://doi.org/10.1182/blood-2019-130435

Published: 2019

Journal Articles

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

Jonathan Bond, Aleksandra Krzywon, Ludovic Lhermitte, MD PhD, Christophe Roumier, PharmD, Anne Roggy, Mohamed Belhocine, PhD MSc, BSc, Alexander Kheirallah, Patrick Villarese, PhD, Guillaume Hypolite, Francine Garnache-Ottou, D.Pharm PhD, Herve Dombret, MD PhD, Nicolas Boissel, MD PhD, Claude Preudhomme, PharmD, PhD, Vahid Asnafi, MD PhD, Elisa Laurenti, PhD, Elizabeth Macintyre, PhDMD

Blood (2019) 134 (Supplement_1): 2511.

https://doi.org/10.1182/blood-2019-125902

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

NARROW

Deletion 17p: a matter of size and number?

Infectious mononucleosis affecting sinonasal mucosa

Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)

UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only